检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors

Jin Li,Shukui Qin,Haijun Zhong,Chuan Jin,Lili Chen,Xianglin Yuan,Qingxia Fan,Kehe Chen,Peiguo Cao,Jianjun Xiao,Da Jiang,Tao Zhang,Hongyu Zhang,Xicheng Wang,Wei Wang,Lin Han,Qingyu Wang,Jun Zhu

JOURNAL OF CLINICAL ONCOLOGY（2022）

引用 0|浏览3
暂无评分
关键词
serplulimab,tumors,microsatellite,instability-high,repair-deficient
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要